The present invention provides metabolites of the antiviral drug bictegravir, including compositions and salts thereof, which are useful in the prevention and/or treatment of HIV as well as analytical methods related to the administration of bictegravir.

The present invention provides metabolites of the antiviral drug bictegravir, including compositions and salts thereof, which are useful in the prevention and/or treatment of HIV as well as analytical methods related to the administration of bictegravir.

The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. These compounds are represented by the following formula (I):

##STR00001##

wherein R.sup.1, R.sup.2, etc. are defined as in claim 1.

The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. These compounds are represented by the following formula (I):

##STR00001##

wherein R.sup.1, R.sup.2, etc. are defined as in claim 1.

Disclosed herein are compositions and pharmaceutical formulations that comprise a binding moiety conjugated to a modified polynucleic acid molecule and a polymer. Also described herein include methods for treating a cancer which utilize a composition or a pharmaceutical formulation comprising a binding moiety conjugated to a polynucleic acid molecule and a polymer.

The present disclosure provides compounds useful for enzymatic glycan remodeling of a glycoprotein. Also provided is a method for remodeling a glycoprotein using M6P-glycan oxazolines in a one-pot deglycosylation/transglycosylation process, which may enable site selective M6P-glycan remodeling of glycoproteins to obtain homogeneous products. The remodeled glycoprotein (such as a recombinant human acid ?-glucosidase) may have enhanced affinity for the CI-MPR, increased uptake by a cell, and improved therapeutic efficacy compared to the original glycoprotein. A method of treating Pompe disease using a glycan remodeled lysosomal enzyme is also provided.

The present disclosure provides compounds useful for enzymatic glycan remodeling of a glycoprotein. Also provided is a method for remodeling a glycoprotein using M6P-glycan oxazolines in a one-pot deglycosylation/transglycosylation process, which may enable site selective M6P-glycan remodeling of glycoproteins to obtain homogeneous products. The remodeled glycoprotein (such as a recombinant human acid ?-glucosidase) may have enhanced affinity for the CI-MPR, increased uptake by a cell, and improved therapeutic efficacy compared to the original glycoprotein. A method of treating Pompe disease using a glycan remodeled lysosomal enzyme is also provided.

Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.

Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein in vivo to treat disorders mediated by the extracellular protein are described.

Compounds and compositions that have a mannose 6-phosphate receptor or ASGPR binding ligand bound to an extracellular protein binding ligand are provided for the selective degradation of a target extracellular protein in vivo to treat disorders mediated by the extracellular protein.